In Phase I/II clinical trials, allogenic CD19-targeted CAR-NK cells achieved promising response rates in patients with B-cell malignancies, as well as an excellent safety profile with no reported cases of severe cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host disease (GvHD)6,7,35. This evidence concerns the gene CD19 and graft versus host disease.